Table 1.
Clinicopathologic Characteristics and Mutation Profiles of Five PPCLs Established from Patient-Derived Xenografts
| ID | Age, years | Sex | Tumor site | Positive lymph nodes/total | Overall survival, mo | K-Ras | TP53 |
|---|---|---|---|---|---|---|---|
| PPCL-46 | 75 | Female | Primary | 7/34 | 10 | G12V | WT |
| PPCL-59 | 73 | Female | Primary | 4/15 | Alive at 4 mo | G12V | WT |
| PPCL-68 | 64 | Female | Primary | 2/18 | Alive at 3 mo | G12D | R248W |
| PPCL-LM1 | 65 | Male | Metastasis | NA | 8 | G12V | WT |
| PPCL-LM2 | 63 | Male | Metastasis | NA | 2 | G12V | WT |
mo, month; NA, not applicable; PPCL, primary pancreatic cancer cell line; WT, wild type.